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We read with interest the VA CARDS (Veterans Affairs Coronary
Artery Revascularization in Diabetes) study (1) comparing percu-
taneous coronary intervention (PCI) and coronary artery bypass
grafting (CABG) in subjects with diabetes. In our opinion, the
most notable finding of the study is not the outcome of the trial,
but the actual study design itself, that is, the stringent
angiography- and clinically based inclusion and exclusion criteria,
which makes application of the study’s findings to real-world
contemporary clinical practice highly questionable. Notably, of the
6,678 diabetic patients screened for this study, a staggering
6,080/6,678 (91%) of screened subjects did not meet angiographic
requirements for the study, and only 198 subjects (3%) were
randomly assigned to either CABG (n  97, 1.5%) or PCI with
drug-eluting stents (DESs) (n  101, 1.5%) and completed the
2-year follow-up. Such a trial design is reminiscent of the PCI
versus CABG randomized trials undertaken before the SYNTAX
(Synergy Between PCI With Taxus and Cardiac Surgery) trial
(2,3), where “cherry-picking” of patients before randomization was
a major confounding issue (2% to 12% of screened patients were
randomized in most trials) that effectively invalidated the results of
these trials (4,5). The SYNTAX trial was designed to overcome
these limitations by incorporating an all-comers design in which
practically no patient was refused entry, with subjects either
randomized (if determined by the Heart Team to achieve “equiv-
alent anatomical revascularization” between CABG and PCI) or
nested in registries (2,3). This was at the insistence of 7 cardiac
surgeons (dubbed the “magnificent 7”) during the design of
SYNTAX to prevent selection bias, a view that was fully endorsed
by the clinical and interventional cardiologists at the time. To give
an example of the potential dangers of using highly selected
populations in a clinical trial design, a recent meta-analysis of
randomized trials undertaken before SYNTAX comparing PCI
with CABG (6) showed CABG to be favored in older subjects and
PCI to be favored in younger subjects, findings that have since
been directly contradicted by the all-comers SYNTAX trial (where
the opposite was shown) (7). In addition, the analyses demonstrat-
ing the anatomic SYNTAX score in the VA CARDS study not to
show any treatment effect between CABG and PCI warrant
specific mention in that they were severely underpowered to draw
any conclusions, even if considered hypothesis generating (8).
Specifically, the majority of subjects in the VA CARDS study had
low (22) (CABG: n  47 vs. PCI: n  59) SYNTAX scores,
with few subjects in the intermediate (23 to 32) (CABG: n  33
vs. PCI: n  24) or high (33) (CABG: n  13 vs. PCI: n  12)
SYNTAX scores, presumably due to the overwhelmingly restric-
tive angiographic inclusion and exclusion criteria of the study as
described earlier, thus making any comparisons of the low with the
higher SYNTAX score tertiles practically meaningless. Even
within the FREEDOM (Future Revascularization Evaluation in
Patients With Diabetes Mellitus: Optimal Management of Mul-
tivessel Disease) trial, (9) analyses based on the SYNTAX score
tertiles appear to have been limited by power and were contra-
dicted by those reported in the pre-stratified and powered diabeticsubgroup of SYNTAX (10). The real lesson of the VA CARDS
study is that randomization of subjects in a clinical trial is not
enough and that an all-comers clinical trial design is warranted.
Anything less will take us back to the confusing era of randomized
trials performed before SYNTAX and will serve to cloud the
medical literature.
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Reply
In the letter about our paper (1), Drs. Farooq and Serruys make the
assertion that the VA CARDS (Veterans Affairs Coronary Artery
Revascularization in Diabetes) study is not applicable to contem-
porary coronary revascularization based on: 1) the angiographic
inclusion criteria being too strict; 2) the small percentage of
screened patients who were enrolled; and 3) that our study was
underpowered to evaluate SYNTAX (Synergy Between PCI With
Taxus and Cardiac Surgery) scores. The letter completely misses
important aspects of our study.
